Amalgamated Financial’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Amalgamated Financial’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$141K	Buy	+4,318	New	+$128K	﹤0.01%	2029

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Amalgamated Financial's RETA Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q1 2022: 4,318 shares worth $141K. The stake represents ﹤0.01% of the portfolio and ranks #2029 among its holdings.

149 funds tracked by Wall St. Rank hold RETA as of Q1 2022.

Amalgamated Financial held 4,318 shares of Reata Pharmaceuticals, Inc. Class A Common Stock worth $141K as of Q1 2022.
Reata Pharmaceuticals, Inc. Class A Common Stock was a new Amalgamated Financial position in Q1 2022.
Reata Pharmaceuticals, Inc. Class A Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2029 holding.
149 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.